Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis

NAEnrolling by invitationINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

January 5, 2017

Primary Completion Date

July 8, 2027

Study Completion Date

July 8, 2027

Conditions
Multiple Sclerosis
Interventions
DIETARY_SUPPLEMENT

N-acetyl Cysteine

The study consists of two arms. The first arm of this study will receive intravenous and oral NAC, a strong antioxidant that increases brain glutathione, which may be beneficial in MS. NAC, is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. It is a common over-the-counter supplement that is also available as an injectable pharmaceutical that protects the liver in cases of acetaminophen overdose. It has the potential to reduce markers of oxidative damage, protect against cell death, and to increase glutathione in blood, which might be useful in preventing oxidative damage in MS patients. The second arm will be a waitlist control receiving standard MS care. It should be noted that both arms will receive standard of care while enrolled into the study.

Trial Locations (1)

19107

Thomas Jefferson University, Philadelphia

All Listed Sponsors
lead

Thomas Jefferson University

OTHER